secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001641172-25-000207
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IMUNON finalizes Phase 3 OVATION 3 trial design with FDA for IMNN-001 in advanced ovarian cancer
--------------------------------------------------------------------------------

- FDA aligns on Phase 3 protocol for IMNN-001 plus NACT vs NACT alone in newly diagnosed advanced ovarian cancer (stage 3/4).
- Primary endpoint is overall survival; secondary endpoints include surgical response, clinical response, time to second-line treatment.
- Phase 2 data showed median OS of 46 months for IMNN-001+NACT vs 33 months for SoC, a 13-month improvement.
- Company initiating trial sites; IMNN-001 manufactured at in-house facility in Huntsville, AL.
- Conference call on March 25, 2025 at 2:00 p.m. ET to discuss Phase 3 OVATION 3 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000164117225000207/0001641172-25-000207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000164117225000207/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer